Laboratoire français de Fractionnement et de Biotechnologies

Biotech

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Activity

Recent Activity

Last 14 days

HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency

Earlier

Details

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

3 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Regulatory

19821 event

FDAJan 1

Opill — OPILL

Application NDA017031 (NDA)

20101 event

FDAAug 13

Ella — ELLA

Application NDA022474 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)